CD19 and B-cell non-Hodgkin lymphoma: Indeed, the first clinical trial (NCT03056339) for CD19-targeting CAR NK cells derived from CB in refractory B cell lymphoma patients reported a positive clinical response in more than 50 % of the individuals with no signs of the above-mentioned side effects [237].